GT Apeiron Therapeutics is a startup based in China.
GT Apeiron Therapeutics is a company headquartered in China.
GT Apeiron Therapeutics is a clinical stage small molecule biotech company developing biomarker-driven cancer therapeutics, including a PRMT5 inhibitor in Phase 1 clinical trials and a KIF18A inhibitor with a differentiated profile.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.